We thank Peggs et al for their experience and views on post-transplant lymphoproliferative disorders (PTLD) following reduced-intensity conditioning regimens. We have now performed 112 reduced-intensity conditioning allografts (56 volunteer unrelated, 56 matched sibling) for myeloid and lymphoid malignancies, using disease-specific conditioning regimens, all containing alemtuzumab (CAM-PATH-1H), with no other proven occurrence of PTLD. There is little doubt that the intensely immunosuppressive properties of these transplant regimens expose the recipient to a high risk of a number of viral infections and a risk of EBV-related PTLD.
We agree that the incidence of PTLD in this population appears to be low, and an incidence of approximately 2% is probably appropriate. This probably reflects the profound T-and B-cell depletion produced by alemtuzumab.
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Meijer et al recently reviewed the data on the monitoring of EBV viral load in diagnosing EBV-associated PTLD, and in standard conditioning BMT recipients, an increase in EBV viral load often preceded the development of PTLD by weeks, with a concomitant reduction in viral load with successful treatment. The sensitivity and specificity of some cell-free systems were 100%. 3 While an increase in EBVviral load does not invariably lead to PLTD, 4 it does identify a high-risk group of patients who will benefit from closer monitoring, and early intervention, for example, by the withdrawal of immunosuppression or treatment with rituximab. The outcome of established aggressive PTLD can be poor [5] [6] [7] [8] [9] and in order to attempt to improve the outcome for these patients, early intervention is imperative and is also much simpler in therapeutic terms.
Reduced-intensity conditioning represents a relatively new and novel approach to allografting, and we are duty bound to attempt to rapidly derive maximal experience with these protocols and their complications. We do intend to pursue a study in order to determine precisely the role of EBV viral load monitoring in the reduced-intensity allograft setting. In the meantime however, while not advocating the routine use of EBV viral load monitoring outside the context of a clinical study, we agree that there must be a high awareness and a low threshold for considering PTLD and EBV-viral load assessments. In groups of patients who have received ATG for refractory GvHD, however, we agree that the risk of PTLD is high and that these patients would benefit, as in any high-risk groups, from EBV viral load monitoring and 'pre-emptive' therapy. 
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